Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21727323 | 0.78 | ESR1 (0.37) | ESR1SMN1; SMN2TDP1MKNK1 | |
| SCHEMBL20321948 | 0.78 | — | — | |
| SCHEMBL25083679 | 0.74 | KMT2A (0.40) | LIMK1 | |
| SCHEMBL24255879 | 0.74 | GAA (0.45) | TDP1 | |
| SCHEMBL25083683 | 0.74 | — | — | |
| SCHEMBL24725742 | 0.70 | — | — | |
| SCHEMBL7648501 | 0.69 | MAPT (0.43) | SMN1; SMN2 | |
| SCHEMBL10168936 | 0.67 | ESR1 (0.59) | ESR1SMN1; SMN2TDP1 | |
| SCHEMBL15094729 | 0.67 | ESR1 (0.59) | ESR1TDP1 | |
| SCHEMBL11553743 | 0.67 | ESR1 (0.40) | ESR1SMN1; SMN2TDP1LIMK1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2023028338-A2 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2022035997-A1 | IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS | AVILAR THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | ESR1 2584/4885SMN1; SMN2 4499/4885TDP1 3930/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | ESR1 2058/4885SMN1; SMN2 4568/4885TDP1 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.